Zhou J, Li J, Papaneri A, Cui G
Neuropharmacology. 2023; 226:109397.
PMID: 36623805
PMC: 9901527.
DOI: 10.1016/j.neuropharm.2022.109397.
Beausejour P, Auclair F, Daghfous G, Ngovandan C, Veilleux D, Zielinski B
J Comp Neurol. 2019; 528(1):114-134.
PMID: 31286519
PMC: 6899967.
DOI: 10.1002/cne.24743.
Herrera-Marschitz M, Meana J, OConnor W, Goiny M, Reid M, Ungerstedt U
Amino Acids. 2013; 2(1-2):157-79.
PMID: 24194283
DOI: 10.1007/BF00806086.
Maheux J, St-Hilaire M, Voyer D, Tirotta E, Borrelli E, Rouillard C
Front Pharmacol. 2012; 3:153.
PMID: 22912617
PMC: 3418524.
DOI: 10.3389/fphar.2012.00153.
Schwarcz R, Guidetti P, Sathyasaikumar K, Muchowski P
Prog Neurobiol. 2009; 90(2):230-45.
PMID: 19394403
PMC: 2829333.
DOI: 10.1016/j.pneurobio.2009.04.005.
Habit formation and the loss of control of an internal clock: inverse relationship between the level of baseline training and the clock-speed enhancing effects of methamphetamine.
Cheng R, Hakak O, Meck W
Psychopharmacology (Berl). 2007; 193(3):351-62.
PMID: 17464501
DOI: 10.1007/s00213-007-0783-2.
Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.
Levey A, Hersch S, Rye D, Sunahara R, Niznik H, Kitt C
Proc Natl Acad Sci U S A. 1993; 90(19):8861-5.
PMID: 8415621
PMC: 47460.
DOI: 10.1073/pnas.90.19.8861.
Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry.
Debonnel G
J Psychiatry Neurosci. 1993; 18(4):157-72.
PMID: 8373754
PMC: 1188525.
Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone.
Sokoloff P, Martres M, Schwartz J
Naunyn Schmiedebergs Arch Pharmacol. 1980; 315(2):89-102.
PMID: 7207647
DOI: 10.1007/BF00499251.
Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum.
Huff R, Molinoff P
Proc Natl Acad Sci U S A. 1982; 79(23):7561-5.
PMID: 6961433
PMC: 347380.
DOI: 10.1073/pnas.79.23.7561.
Interaction of pergolide with central dopaminergic receptors.
Goldstein M, Lieberman A, Lew J, Asano T, Rosenfeld M, MAKMAN M
Proc Natl Acad Sci U S A. 1980; 77(6):3725-8.
PMID: 6932044
PMC: 349691.
DOI: 10.1073/pnas.77.6.3725.
Proceedings of the British Pharmacological Society. 5th-7th January, 1983. Abstracts.
Br J Pharmacol. 1983; 78 Suppl:1P-187P.
PMID: 6831120
PMC: 2044687.
Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.
Bannon M, Bunney E, Zigun J, Skirboll L, Roth R
Naunyn Schmiedebergs Arch Pharmacol. 1980; 312(2):161-5.
PMID: 6772975
DOI: 10.1007/BF00569725.
Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
Hall M, Jenner P, Kelly E, Marsden C
Br J Pharmacol. 1983; 79(2):599-610.
PMID: 6418246
PMC: 2044886.
DOI: 10.1111/j.1476-5381.1983.tb11035.x.
Pharmacodynamic effects and possible therapeutic uses of THIP, a specific GABA-agonist.
Christensen A, Svendsen O, Krogsgaard-Larsen P
Pharm Weekbl Sci. 1982; 4(5):145-53.
PMID: 6292818
DOI: 10.1007/BF01959034.
Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions.
Markstein R
J Neural Transm. 1981; 51(1-2):39-59.
PMID: 6267192
DOI: 10.1007/BF01664004.
Uptake of radiocalcium by nerve endings isolated from rat brain: pharmacological studies.
GRIPENBERG J, Heinonen E, Jansson S
Br J Pharmacol. 1980; 71(1):273-8.
PMID: 6258689
PMC: 2044403.
DOI: 10.1111/j.1476-5381.1980.tb10936.x.
Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina.
MAKMAN M, Dvorkin B, Klein P
Proc Natl Acad Sci U S A. 1982; 79(13):4212-6.
PMID: 6213964
PMC: 346608.
DOI: 10.1073/pnas.79.13.4212.
Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites.
Martres M, Sokoloff P, Delandre M, Schwartz J, Protais P, Costentin J
Naunyn Schmiedebergs Arch Pharmacol. 1984; 325(2):102-15.
PMID: 6144046
DOI: 10.1007/BF00506189.
Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
Gale K, Casu M
Mol Cell Biochem. 1981; 39:369-405.
PMID: 6118827
DOI: 10.1007/BF00232586.
